„Aging Clock“ enthüllt Alterungsprozesse in Immunzellen
Mit dem Alter verändert sich nicht nur unser Körper, sondern auch unser Immunsystem. Wie genau Immunzellen altern und we…
Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older
Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) h…
Infection prevention in motion
According to recent studies, between 400,000 and 600,000 people suffer hospital infections every year. A significant pro…
Positive Phase-II-Daten aus klinischer Studie zu RECCE® 327 Gel unterstützen Beschleunigung des Vermarktungsprozesses
Wichtigste Eckdaten: - Erfolg in klinischer Phase-II-Studie zur Beurteilung der Wirksamkeit und Sicherheit von RECCE® 3…
ERC Proof of Concept Grant für Yang Li
Der Europäische Forschungsrat (ERC) hat die Ergebnisse der letzten Runde seines Wettbewerbs „Proof of Concept Grant“ 202…
MedMira Receives Investigational Testing Authorizations for Multiplo® TP/HIV Self-Test and Non-Professional Use Applications
MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received Investigational Testing Authorizations (ITAs) fr…
MedMira receives Health Canada approval for its Multiplo® Rapid (TP/HIV) Test for Syphilis and HIV
MedMira Inc. (MedMira) (TSXV: MIR) announced today that it has received today, on December 24, 2024, the approval from H…
MedMira Reports FY2024 Update
. Corporate Update In December 2023, the Company received the 510(k) (FDA) approval for its Reveal® G4 Rapid HIV-1/2 an…
CeGaT Enhances ExomeXtra® for Deeper Genetic Insights
CeGaT, a global provider of genetic diagnostics and sequencing services, announces significant advancements in exome dia…
First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic’s Mpox Vaccine
Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN® mpox/smallpox vaccine…